Hemato-oncology chromosomal microarray
GTR Test Accession: Help GTR000527837.1
CANCERINHERITED DISEASEINHERITED DISEASE SUSCEPTIBILITY ... View more
Last updated in GTR: 2015-08-16
Last annual review date for the lab: 2023-05-22 LinkOut
At a Glance
Diagnosis; Prognostic; Risk Assessment; ...
Neuroblastoma; Acute lymphoid leukemia; Basal cell carcinoma, susceptibility to, 1; ...
ABI1 (10p12.1), ACSL3 (2q36.1), AKT1 (14q32.33), AKT2 (19q13.2), ALK (2p23.2-23.1), ...
Molecular Genetics - Deletion/duplication analysis: Microarray; ...
Not provided
Not provided
Not provided
Ordering Information
Offered by: Help
Pittsburgh Cytogenetics Laboratory
View lab's website
View lab's test page
Test short name: Help
Kancerray
Specimen Source: Help
Who can order: Help
  • Health Care Provider
How to Order: Help
For more information, please contact the laboratory directly.
Informed consent required: Help
Decline to answer
Pre-test genetic counseling required: Help
Decline to answer
Post-test genetic counseling required: Help
Decline to answer
Recommended fields not provided:
Conditions Help
Total conditions: 23
Condition/Phenotype Identifier
Test Targets
Chromosomal regions/Mitochondria Help
Total chromosomal regions/mitochondria: 1
Chromosomal region/Mitochondrion Associated condition
Genes Help
Total genes: 92
Gene Associated Condition Germline or Somatic Allele (Lab-provided) Variant in NCBI
Methodology
Total methods: 2
Method Category Help
Test method Help
Instrument *
Deletion/duplication analysis
Microarray
Detection of homozygosity
Microarray
* Instrument: Not provided
Clinical Information
Test purpose: Help
Diagnosis; Prognostic; Risk Assessment; Therapeutic management
Recommended fields not provided:
Technical Information
Test Comments: Help
For a specific gene information, please contact the laboratory directly.
Availability: Help
Tests performed
Entire test performed in-house
Analytical Validity: Help
This test is evaluated for analytical validity using an established validation process utilizing abnormal and normal specimens as per CAP, ACMG, and CLIA guidelines. Microarray platform includes oligonucleotide probes for the 898 genes known to be involved in carcinogenesis, subtelomeric, pericentromeric regions, as well as breakpoint “hot spot” intervals associated … View more
Assay limitations: Help
Although microarray detects microscopic and submicroscopic deletions and duplications undetectable by karyotyping, microarray will not detect balanced chromosome rearrangements, such as balanced translocations or inversions. It will not detect alterations in chromosome structure at areas of the genome not covered by the array. This technology will not detect sequence alterations … View more
Proficiency testing (PT):
Is proficiency testing performed for this test? Help
No

Description of internal test validation method: Help
Karyotype, FISH analysis
Recommended fields not provided:
Regulatory Approval
FDA Review: Help
Not provided
Additional Information

IMPORTANT NOTE: NIH does not independently verify information submitted to GTR; it relies on submitters to provide information that is accurate and not misleading. NIH makes no endorsements of tests or laboratories listed in GTR. GTR is not a substitute for medical advice. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.